Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by AnalystsMarket Beat·1 day ago, 01:14 AMCSTL-3.12%
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test | CSTL Stock NewsStockTitan·Jul 14 at 07:30 AMCSTL-3.12%
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 | CSTL Stock NewsStockTitan·Jul 8 at 10:00 PMCSTL-3.12%
Castle Biosciences COO Kristen Oelschlager sells 8,586 shares for $209,041.2PUBT·Jul 6 at 03:25 PMCSTL-3.12%
Castle Biosciences, Inc. $CSTL Shares Sold by Wasatch Advisors LPMarket Beat·Jun 28 at 05:24 AMCSTL-3.12%
Castle Biosciences says DecisionDx-Melanoma i31-SLNB beats MIA nomogram in prospective SLNB risk studyPUBT·Jun 25 at 03:30 PMCSTL-3.12%
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga_article·Jun 25 at 07:44 AMTNXP-6.97%CSTL-3.12%
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy | CSTL Stock NewsStockTitan·Jun 25 at 07:30 AMCSTL-3.12%
